In this guest column, Scott Mazza of Vitality CBD examines emerging preclinical research on CBD’s potential role in alleviating menopause-related symptoms. Citing a first-of-its-kind study published in Frontiers in Pharmacology, Mazza explains how CBD influenced metabolism, inflammation, bone density, and gut health in estrogen-deficient models, while emphasizing the need for further human research, rigorous product standards, and third-party testing as interest in CBD-based menopause support continues to grow.

In this op-ed, Scott Mazza of Vitality CBD examines Canada’s cannabis legalization missteps to outline practical lessons for New York as it rolls out adult-use sales. Drawing on Canada’s experience with overproduction, overregulation, and persistent illicit markets, Mazza argues that balanced supply, flexible regulation, and meaningful inclusion of legacy operators are essential to building a sustainable, competitive legal cannabis market in New York.

In this guest column, Scott Mazza, co-founder and COO of Vitality CBD, outlines three key policy changes he believes should be addressed in the 2023 Farm Bill to bring clarity and stability to the CBD market. Mazza argues for FDA approval of CBD as a dietary supplement, clear federal treatment of Delta-8 THC, and a revised THC threshold for hemp, positioning regulatory certainty as essential for consumer safety, product quality, and long-term industry growth.

In this guest column, Scott Mazza, co-founder and COO of Vitality CBD, examines what current research does—and does not—tell us about CBD salves for pain management and athletic recovery. Mazza outlines the compound’s anti-inflammatory potential, growing adoption among professional athletes, and the need for stronger clinical evidence and product standards, emphasizing third-party testing and quality controls as essential safeguards as interest in CBD-based alternatives to opioids continues to grow.

In this op-ed, Scott Mazza, co-founder and COO of Vitality CBD, argues that continued FDA inaction on approving CBD as a dietary supplement is putting consumers at risk and undermining industry credibility. Mazza explains how the lack of federal standards enables unsafe products and misleading claims, and calls for clear regulatory approval to legitimize CBD, protect consumers, and support evidence-based research and responsible manufacturers.

In this guest column, Scott Mazza of Vitality CBD examines the growing acceptance of CBD in professional sports following Major League Baseball’s decision to allow CBD sponsorships. Drawing on developments across the MLB, NFL, and UFC, Mazza explains why CBD aligns with athlete recovery and consumer awareness, while outlining the regulatory and advertising constraints companies must navigate as CBD enters mainstream sports media.

In this guest column, Scott Mazza of Vitality CBD explains why organic cultivation and extraction standards are critical to ensuring safe, high-quality CBD products. Drawing on research and industry testing data, Mazza details how pesticides, heavy metals, and poor extraction methods compromise product integrity, and outlines why USDA organic certification and third-party lab testing are essential safeguards for consumers seeking clean, accurately labeled hemp-derived CBD.

In this opinion piece, Scott Mazza, co-founder and COO of Vitality CBD, calls attention to widespread quality and compliance failures in New York’s CBD market, citing inaccurate labeling, contamination risks, and weak enforcement. Drawing on regulatory developments and industry investigations, Mazza urges stronger oversight alongside informed consumer pressure, arguing that transparent third-party testing and accountability are essential to protecting consumers and restoring trust in hemp-derived CBD products.

In this guest column, Scott Mazza, co-founder and COO of Vitality CBD, calls for stricter enforcement of third-party lab testing and quality controls in New York’s hemp-derived CBD market. Drawing on industry data and investigative findings, Mazza explains how weak compliance around potency, purity, and labeling puts consumers at risk, and argues that transparent testing, consumer pressure, and producer-led standards are essential to restoring trust and accountability in the state’s CBD ecosystem.

In this educational feature, Vitality CBD draws on firsthand testing experience to highlight why third-party purity and potency testing is essential in today’s largely unregulated cannabis and CBD market. Using real product analyses and industry investigations, the piece explains how inaccurate labeling and lack of oversight put consumers at risk, while outlining practical standards like transparent dosing, organic sourcing, and independent lab verification that Vitality CBD views as critical for consumer trust and product safety.